FG-4592 (BioDeep_00000272705)
代谢物信息卡片
Roxadustat
化学式: C19H16N2O5 (352.1059166)
中文名称: 罗沙司他
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3
InChI: InChI=1S/C19H16N2O5/c1-11-15-9-13(26-12-5-3-2-4-6-12)7-8-14(15)18(24)17(21-11)19(25)20-10-16(22)23/h2-9,24H,10H2,1H3,(H,20,25)(H,22,23)
描述信息
B - Blood and blood forming organs > B03 - Antianemic preparations
C471 - Enzyme Inhibitor
Roxadustat is an orally active hypoxia-inducible factor (HIF) prolyl-hydroxylase (PHD) inhibitor (HIF-PHI) that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin[1].
同义名列表
2 个代谢物同义名
数据库引用编号
8 个数据库交叉引用编号
- ChEBI: CHEBI:132774
- KEGGdrug: D10593
- PubChem: 11256664
- DrugBank: DB04847
- ChEMBL: CHEMBL2338329
- CAS: 808118-40-3
- PMhub: MS000004209
- medchemexpress: HY-13426
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Xiaoe You, Baochun Guo, Zhen Wang, Hualin Ma, Lixia Liu, Ru Zhou, Yaxuan Zheng, Xinzhou Zhang. Integrated proteomic and metabolomic profiling of urine of renal anemia patients uncovers the molecular mechanisms of roxadustat.
Molecular omics.
2023 07; 19(6):473-483. doi:
10.1039/d3mo00015j. [PMID: 37039271] - Tong Wu, Yuanyuan Qi, Shuang Ma, Lijie Zhang, Xinyu Pu, Kui Chen, Ying Zhao, Shenghua Sang, Jing Xiao. Efficacy of Roxadustat on anemia and residual renal function in patients new to peritoneal dialysis.
Renal failure.
2022 Dec; 44(1):529-540. doi:
10.1080/0886022x.2022.2050754. [PMID: 35318873] - Xiaodong Su, Yuan Xie, Junwen Zhang, Mingxin Li, Qing Zhang, Guishan Jin, Fusheng Liu. HIF-α activation by the prolyl hydroxylase inhibitor roxadustat suppresses chemoresistant glioblastoma growth by inducing ferroptosis.
Cell death & disease.
2022 10; 13(10):861. doi:
10.1038/s41419-022-05304-8. [PMID: 36209275] - Xin Zheng, Xia Chen, Tao Liu, Ji Jiang, Xinge Cui, Qian Zhao, Pei Hu. Liquid chromatography-tandem mass spectrometry methods for quantification of roxadustat (FG-4592) in human plasma and urine and the applications in two clinical pharmacokinetic studies.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2022 Jul; 1203(?):123274. doi:
10.1016/j.jchromb.2022.123274. [PMID: 35662878] - Akira Mima, Yasuhiro Horii. Treatment of Renal Anemia in Patients With Hemodialysis Using Hypoxia-inducible Factor (HIF) Stabilizer, Roxadustat: A Short-term Clinical Study.
In vivo (Athens, Greece).
2022 Jul; 36(4):1785-1789. doi:
10.21873/invivo.12892. [PMID: 35738640] - Lingling Bao, Xueyan Bian, Aiwei Zhang, Jiancheng Huang, Liling Ren, Chunlei Luo. Long-term efficacy, safety, and medication compliance of roxadustat on peritoneal dialysis patients with renal anemia affected by the COVID-19 pandemic: a retrospective study.
Annals of palliative medicine.
2022 Jun; 11(6):2017-2024. doi:
10.21037/apm-22-555. [PMID: 35817736] - Qiu Li, Benqiang Yao, Shiting Zhao, Zhou Lu, Yan Zhang, Qiuping Xiang, Xishan Wu, Haonan Yu, Cheng Zhang, Junhua Li, Xiaoxi Zhuang, Donghai Wu, Yong Li, Yong Xu. Discovery of a Highly Selective and H435R-Sensitive Thyroid Hormone Receptor β Agonist.
Journal of medicinal chemistry.
2022 05; 65(10):7193-7211. doi:
10.1021/acs.jmedchem.2c00144. [PMID: 35507418] - Dorien Groenendaal-van de Meent, Martin den Adel, Virginie Kerbusch, Jan van Dijk, Tomohisa Shibata, Kota Kato, Marloes Schaddelee. Effect of Roxadustat on the Pharmacokinetics of Simvastatin, Rosuvastatin, and Atorvastatin in Healthy Subjects: Results From 3 Phase 1, Open-Label, 1-Sequence, Crossover Studies.
Clinical pharmacology in drug development.
2022 04; 11(4):486-501. doi:
10.1002/cpdd.1076. [PMID: 35182045] - Katsuyuki Miki, Yuki Nakamura, Takayoshi Yokoyama, Manabu Kamiyama, Yasuo Ishii. Therapeutic Effect of Roxadustat on Patients With Posttransplant Anemia.
Transplantation proceedings.
2022 Apr; 54(3):671-677. doi:
10.1016/j.transproceed.2022.02.004. [PMID: 35256197] - Steven Fishbane, Carol A Pollock, Mohamed El-Shahawy, Elizabeth T Escudero, Anjay Rastogi, Bui Pham Van, Lars Frison, Mark Houser, Maksym Pola, Dustin J Little, Nicolas Guzman, Pablo E Pergola. Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study.
Journal of the American Society of Nephrology : JASN.
2022 04; 33(4):850-866. doi:
10.1681/asn.2020111638. [PMID: 35361724] - David Czock, Frieder Keller. Clinical Pharmacokinetics and Pharmacodynamics of Roxadustat.
Clinical pharmacokinetics.
2022 03; 61(3):347-362. doi:
10.1007/s40262-021-01095-x. [PMID: 34905154] - Taku Nakai, Daisuke Saigusa, Yuma Iwamura, Yotaro Matsumoto, Keiko Umeda, Koichiro Kato, Hayato Yamaki, Yoshihisa Tomioka, Ikuo Hirano, Seizo Koshiba, Masayuki Yamamoto, Norio Suzuki. Esterification promotes the intracellular accumulation of roxadustat, an activator of hypoxia-inducible factors, to extend its effective duration.
Biochemical pharmacology.
2022 03; 197(?):114939. doi:
10.1016/j.bcp.2022.114939. [PMID: 35114188] - Li Zheng, Jinhui Tian, Deping Liu, Yan Zhao, Xiaoyong Fang, Yatong Zhang, Yuming Liu. Efficacy and safety of roxadustat for anaemia in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: A systematic review and meta-analysis.
British journal of clinical pharmacology.
2022 03; 88(3):919-932. doi:
10.1111/bcp.15055. [PMID: 34428860] - Aline Jatho, Anke Zieseniss, Katja Brechtel-Curth, Jia Guo, Kai Oliver Böker, Gabriela Salinas, Roland H Wenger, Dörthe M Katschinski. The HIFα-Stabilizing Drug Roxadustat Increases the Number of Renal Epo-Producing Sca-1+ Cells.
Cells.
2022 02; 11(4):. doi:
10.3390/cells11040753. [PMID: 35203399] - Yukiko Yasuoka, Yuichiro Izumi, Takashi Fukuyama, Haruki Omiya, Truyen D Pham, Hideki Inoue, Tomomi Oshima, Taiga Yamazaki, Takayuki Uematsu, Noritada Kobayashi, Yoshitaka Shimada, Yasushi Nagaba, Tetsuro Yamashita, Masashi Mukoyama, Yuichi Sato, Susan M Wall, Jeff M Sands, Noriko Takahashi, Katsumasa Kawahara, Hiroshi Nonoguchi. Effects of Roxadustat on Erythropoietin Production in the Rat Body.
Molecules (Basel, Switzerland).
2022 Feb; 27(3):. doi:
10.3390/molecules27031119. [PMID: 35164384] - Akitsugu Takada, Tomohisa Shibata, Takanori Shiga, Dorien Groenendaal-van de Meent, Kanji Komatsu. Population pharmacokinetics of roxadustat in Japanese dialysis-dependent chronic kidney disease patients with anaemia.
British journal of clinical pharmacology.
2022 02; 88(2):787-797. doi:
10.1111/bcp.15023. [PMID: 34350625] - Mei Zhang, Rong Dong, Jing Yuan, Jingjing Da, Yan Zha, Yanjun Long. Roxadustat (FG-4592) protects against ischaemia/reperfusion-induced acute kidney injury through inhibiting the mitochondrial damage pathway in mice.
Clinical and experimental pharmacology & physiology.
2022 02; 49(2):311-318. doi:
10.1111/1440-1681.13601. [PMID: 34653291] - David H Henry, John Glaspy, Rosemary Harrup, Moshe Mittelman, Amy Zhou, Hetty E Carraway, Charles Bradley, Gopal Saha, Katharina Modelska, Pamela Bartels, Robert Leong, Kin-Hung P Yu. Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: Open-label, dose-selection, lead-in stage of a phase 3 study.
American journal of hematology.
2022 02; 97(2):174-184. doi:
10.1002/ajh.26397. [PMID: 34724251] - Yan-Pei Hou, Xin-Yue Mao, Chang Wang, Zhi-Hui Xu, Zhi-Hua Bu, Meng Xu, Bing Li. Roxadustat treatment for anemia in peritoneal dialysis patients: A randomized controlled trial.
Journal of the Formosan Medical Association = Taiwan yi zhi.
2022 Feb; 121(2):529-538. doi:
10.1016/j.jfma.2021.06.004. [PMID: 34167878] - Basel Abdelazeem, Joseph Shehata, Kirellos Said Abbas, Nahla Ahmed El-Shahat, Bilal Malik, Pramod Savarapu, Mostafa Eltobgy, Arvind Kunadi. The efficacy and safety of roxadustat for the treatment of anemia in non-dialysis dependent chronic kidney disease patients: An updated systematic review and meta-analysis of randomized clinical trials.
PloS one.
2022; 17(4):e0266243. doi:
10.1371/journal.pone.0266243. [PMID: 35363823] - Yu Kurata, Tetsuhiro Tanaka, Masaomi Nangaku. An evaluation of roxadustat for the treatment of anemia associated with chronic kidney disease.
Expert opinion on pharmacotherapy.
2022 Jan; 23(1):19-28. doi:
10.1080/14656566.2021.1993821. [PMID: 34686069] - Sijia Li, Xueqin Chen, Penghua Hu, Suijing Wu, Jianchao Ma, Zhuo Li, Xiuchuan Wu, Feng Wen, Xia Fu, Zhonglin Feng, Yiming Tao, Bohou Li, Lei Fu, Renwei Huang, Chaosheng He, Wei Shi, Xinling Liang, Shuangxin Liu. Roxadustat Improves Erythropoietin Antibody-Mediated Pure Red Cell Aplasia in a Patient with Hemodialysis.
Blood purification.
2022; 51(2):189-192. doi:
10.1159/000513423. [PMID: 34500449] - A-Feng Miao, Jian-Xiang Liang, Lei Yao, Jun-Ling Han, Li-Juan Zhou. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against renal ischemia/reperfusion injury by inhibiting inflammation.
Renal failure.
2021 Dec; 43(1):803-810. doi:
10.1080/0886022x.2021.1915801. [PMID: 33966598] - Yue Zhou, Xiao-Xia Chen, Ya-Feng Zhang, Ji-Zhuang Lou, Hong-Bo Yuan. Roxadustat for dialysis patients with erythropoietin hypo-responsiveness: a single-center, prospective investigation.
Internal and emergency medicine.
2021 Nov; 16(8):2193-2199. doi:
10.1007/s11739-021-02738-4. [PMID: 34021853] - Jun Li, Kuifen Ma, Liangping Wang, Huaji Qi, Junhao Lv, Yuefeng Rao, Wenhan Peng. Efficacy and safety of roxadustat in the treatment of renal allograft anemia patients: a case series.
Annals of palliative medicine.
2021 Nov; 10(11):11859-11867. doi:
10.21037/apm-21-2916. [PMID: 34872310] - Junjie Chen, Zhi Li, Hao Zhang, Jing Hu, Jianwen Wang, Huang Zhou, Yan Liu, Jun Liu, Bin Yi, Wei Zhang. A Prospective, Self-Controlled Pilot Study of the Efficacy of Roxadustat for Erythropoietin Hyporesponsiveness in Patients Requiring Chronic Ambulatory Peritoneal Dialysis.
Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.
2021 Oct; ?(?):. doi:
10.1053/j.jrn.2021.09.003. [PMID: 34756787] - Samuele Iesari, Isabelle Leclercq, Nicolas Joudiou, Mina Komuta, Aurélie Daumerie, Jérôme Ambroise, Alexandra Dili, Natacha Feza-Bingi, Daela Xhema, Caroline Bouzin, Bernard Gallez, Francesco Pisani, Eliano Bonaccorsi-Riani, Pierre Gianello. Selective HIF stabilization alleviates hepatocellular steatosis and ballooning in a rodent model of 70\% liver resection.
Clinical science (London, England : 1979).
2021 10; 135(19):2285-2305. doi:
10.1042/cs20210183. [PMID: 34550341] - Botond Csiky, Michael Schömig, Ciro Esposito, Jonathan Barratt, Michael Reusch, Udaya Valluri, Wladyslaw Sulowicz. Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES).
Advances in therapy.
2021 10; 38(10):5361-5380. doi:
10.1007/s12325-021-01904-6. [PMID: 34537926] - Jonathan Barratt, Wladyslaw Sulowicz, Michael Schömig, Ciro Esposito, Michael Reusch, James Young, Botond Csiky. Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.
Advances in therapy.
2021 10; 38(10):5345-5360. doi:
10.1007/s12325-021-01903-7. [PMID: 34523074] - Tadao Akizawa, Yusuke Yamaguchi, Yoshikatsu Majikawa, Michael Reusch. Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients.
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
2021 Oct; 25(5):575-585. doi:
10.1111/1744-9987.13609. [PMID: 33200512] - Jiaxin Zhao, Yanyan Xu, Jingyuan Xie, Junling Liu, Ruiyan Zhang, Xiaoxiang Yan. Roxadustat Does Not Affect Platelet Production, Activation, and Thrombosis Formation.
Arteriosclerosis, thrombosis, and vascular biology.
2021 10; 41(10):2523-2537. doi:
10.1161/atvbaha.121.316495. [PMID: 34348487] - Jing Yu, Shuqin Wang, Wei Shi, Wei Zhou, Yujia Niu, Songming Huang, Yue Zhang, Aihua Zhang, Zhanjun Jia. Roxadustat prevents Ang II hypertension by targeting angiotensin receptors and eNOS.
JCI insight.
2021 09; 6(18):. doi:
10.1172/jci.insight.133690. [PMID: 34403364] - Boye L Jensen. Get use to the -dustats: Roxadustat and molidustat, members of the hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor drug class promote kidney function, perfusion and oxygenation in rats through nitric oxide.
Acta physiologica (Oxford, England).
2021 09; 233(1):e13706. doi:
10.1111/apha.13706. [PMID: 34143560] - Qiyan Zheng, Huisheng Yang, Xinwen Fu, Yishan Huang, Ruojun Wei, Yahui Wang, Yu Ning Liu, Wei Jing Liu. The efficacy and safety of roxadustat for anemia in patients with chronic kidney disease: a meta-analysis.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2021 08; 36(9):1603-1615. doi:
10.1093/ndt/gfaa110. [PMID: 33051677] - Robert Provenzano, Evgeny Shutov, Liubov Eremeeva, Svitlana Korneyeva, Lona Poole, Gopal Saha, Charles Bradley, Meraf Eyassu, Anatole Besarab, Robert Leong, Cameron S Liu, Thomas B Neff, Lynda Szczech, Kin-Hung P Yu. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2021 08; 36(9):1717-1730. doi:
10.1093/ndt/gfab051. [PMID: 33629100] - Evgeny Shutov, Władysław Sułowicz, Ciro Esposito, Avtandil Tataradze, Branislav Andric, Michael Reusch, Udaya Valluri, Nada Dimkovic. Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS).
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2021 08; 36(9):1629-1639. doi:
10.1093/ndt/gfab057. [PMID: 33630072] - Jonathan Barratt, Branislav Andric, Avtandil Tataradze, Michael Schömig, Michael Reusch, Udaya Valluri, Christophe Mariat. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES).
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2021 08; 36(9):1616-1628. doi:
10.1093/ndt/gfab191. [PMID: 34077510] - Robert Provenzano, Lynda Szczech, Robert Leong, Khalil G Saikali, Ming Zhong, Tyson T Lee, Dustin J Little, Mark T Houser, Lars Frison, John Houghton, Thomas B Neff. Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials.
Clinical journal of the American Society of Nephrology : CJASN.
2021 08; 16(8):1190-1200. doi:
10.2215/cjn.16191020. [PMID: 34362786] - Mengqiu Wu, Weiyi Chen, Mengqiu Miao, Qianqian Jin, Shengnan Zhang, Mi Bai, Jiaojiao Fan, Yue Zhang, Aihua Zhang, Zhanjun Jia, Songming Huang. Anti-anemia drug FG4592 retards the AKI-to-CKD transition by improving vascular regeneration and antioxidative capability.
Clinical science (London, England : 1979).
2021 07; 135(14):1707-1726. doi:
10.1042/cs20210100. [PMID: 34255035] - Rui Wu, Yanqiang Peng. Roxadustat on anti-erythropoietin antibody-related pure red cell aplasia in the patient with end-stage renal disease.
Seminars in dialysis.
2021 07; 34(4):319-322. doi:
10.1111/sdi.12991. [PMID: 34128578] - Li Zhang, Jie Hou, Jia Li, Sen-Sen Su, Shuai Xue. Roxadustat for the treatment of anemia in patients with chronic kidney diseases: a meta-analysis.
Aging.
2021 06; 13(13):17914-17929. doi:
10.18632/aging.203143. [PMID: 34115611] - Dinko Rekić, Virginie Kerbusch-Herben, Mats Någård, James Chou, Jiayin Huang, Charles Bradley, Magnus Åstrand, Stacey Tannenbaum, Bengt Hamrén. Pharmacokinetics of Roxadustat: A Population Analysis of 2855 Dialysis- and Non-Dialysis-Dependent Patients with Chronic Kidney Disease.
Clinical pharmacokinetics.
2021 06; 60(6):759-773. doi:
10.1007/s40262-020-00974-z. [PMID: 33486718] - Dorien Groenendaal-van de Meent, Virginie Kerbusch, Begona Barroso-Fernandez, Martin den Adel, Jan van Dijk, Georg Golor, Marloes Schaddelee. Effect of the Phosphate Binders Sevelamer Carbonate and Calcium Acetate on the Pharmacokinetics of Roxadustat After Concomitant or Time-separated Administration in Healthy Individuals.
Clinical therapeutics.
2021 06; 43(6):1079-1091. doi:
10.1016/j.clinthera.2021.03.025. [PMID: 33962762] - Qin Yang, Xin Wang. A case report of rhabdomyolysis caused by the use of roxadustat in the treatment caused by renal anaemia.
International journal of clinical practice.
2021 Jun; 75(6):e14011. doi:
10.1111/ijcp.14011. [PMID: 33411966] - Binoy Mathew, Moses Philip, Zubair Perwad, Tajudheen K Karatt, Marina Rodriguez Caveney, Michael Benedict Subhahar, Abdul Khader Karakka Kal. Identification of Hypoxia-inducible factor (HIF) stabilizer roxadustat and its possible metabolites in thoroughbred horses for doping control.
Drug testing and analysis.
2021 Jun; 13(6):1203-1215. doi:
10.1002/dta.3014. [PMID: 33569900] - Suhui Qie, Ning Jiao, Kunfeng Duan, Jingxin Li, Yang Liu, Guoqiang Liu. The efficacy and safety of roxadustat treatment for anemia in patients with kidney disease: a meta-analysis and systematic review.
International urology and nephrology.
2021 May; 53(5):985-997. doi:
10.1007/s11255-020-02693-7. [PMID: 33389461] - Peter A C Wing, Thomas P Keeley, Xiaodong Zhuang, Jeffrey Y Lee, Maria Prange-Barczynska, Senko Tsukuda, Sophie B Morgan, Adam C Harding, Isobel L A Argles, Samvid Kurlekar, Marko Noerenberg, Craig P Thompson, Kuan-Ying A Huang, Peter Balfe, Koichi Watashi, Alfredo Castello, Timothy S C Hinks, William James, Peter J Ratcliffe, Ilan Davis, Emma J Hodson, Tammie Bishop, Jane A McKeating. Hypoxic and pharmacological activation of HIF inhibits SARS-CoV-2 infection of lung epithelial cells.
Cell reports.
2021 04; 35(3):109020. doi:
10.1016/j.celrep.2021.109020. [PMID: 33852916] - Hui Wang, Ke Huang, Chun Wang, Chunyan Chen, Hui Fang, Jin Cao. Effectiveness and safety of roxadustat in the treatment of anemia of kidney disease: a systematic review and meta-analysis.
Annals of palliative medicine.
2021 Apr; 10(4):4736-4746. doi:
10.21037/apm-21-456. [PMID: 33966423] - Ke-Dan Cai, Bei-Xia Zhu, Hai-Xue Lin, Qun Luo. Successful application of roxadustat in the treatment of patients with anti-erythropoietin antibody-mediated renal anaemia: a case report and literature review.
The Journal of international medical research.
2021 Apr; 49(4):3000605211005984. doi:
10.1177/03000605211005984. [PMID: 33853432] - Naoko Katagiri, Hirofumi Hitomi, Shin-Ichi Mae, Maki Kotaka, Li Lei, Takuya Yamamoto, Akira Nishiyama, Kenji Osafune. Retinoic acid regulates erythropoietin production cooperatively with hypoxia-inducible factors in human iPSC-derived erythropoietin-producing cells.
Scientific reports.
2021 02; 11(1):3936. doi:
10.1038/s41598-021-83431-6. [PMID: 33594180] - Monica Mazzarino, Ilaria Perretti, Carlotta Stacchini, Fabio Comunità, Xavier de la Torre, Francesco Botrè. UPLC-MS-Based Procedures to Detect Prolyl-Hydroxylase Inhibitors of HIF in Urine.
Journal of analytical toxicology.
2021 Feb; 45(2):184-194. doi:
10.1093/jat/bkaa055. [PMID: 32435795] - Władysław Grzeszczak, Dariusz Szczyra, Mirosław Śnit. Whether Prolyl Hydroxylase Blocker-Roxadustat-In the Treatment of Anemia in Patients with Chronic Kidney Disease Is the Future?.
International journal of environmental research and public health.
2021 02; 18(4):. doi:
10.3390/ijerph18041612. [PMID: 33567688] - Mercedes Kile, Patcharaporn Sudchada. Current treatment practices for anemia in patients with chronic kidney disease and future opportunities with hypoxia-inducible factor prolyl hydroxylase inhibitors: a narrative review.
International urology and nephrology.
2021 Feb; 53(2):283-290. doi:
10.1007/s11255-020-02584-x. [PMID: 32770437] - Laurie De Wilde, Kris Roels, Koen Deventer, Peter Van Eenoo. Automated sample preparation for the detection and confirmation of hypoxia-inducible factor stabilizers in urine.
Biomedical chromatography : BMC.
2021 Feb; 35(2):e4970. doi:
10.1002/bmc.4970. [PMID: 32840903] - Yaling Zhang, Song Ren, Hen Xue, Amanda Y Wang, Yang Zou, Yanrong Cai, Jingdong He, Xiaoling Yuan, Feifei Jiang, Jinxi Wei, Dongmei Yang, Dong He, Shide Hu, Min Lei, Fei Deng, Jin Chen, Xia Wang, Qiang He, Guisen Li, Daqing Hong. Roxadustat in treating anemia in dialysis patients (ROAD): protocol and rationale of a multicenter prospective observational cohort study.
BMC nephrology.
2021 01; 22(1):28. doi:
10.1186/s12882-021-02229-w. [PMID: 33441103] - Dorien Groenendaal-van de Meent, Virginie Kerbusch, Rudiger Kaspera, Begona Barroso-Fernandez, Piergiorgio Galletti, Gernot K Klein, Martin den Adel. Effect of Kidney Function and Dialysis on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
European journal of drug metabolism and pharmacokinetics.
2021 Jan; 46(1):141-153. doi:
10.1007/s13318-020-00658-w. [PMID: 33165773] - Theodoros Eleftheriadis, Georgios Pissas, Georgios Filippidis, Vassilios Liakopoulos, Ioannis Stefanidis. Reoxygenation induces reactive oxygen species production and ferroptosis in renal tubular epithelial cells by activating aryl hydrocarbon receptor.
Molecular medicine reports.
2021 01; 23(1):. doi:
10.3892/mmr.2020.11679. [PMID: 33179104] - Tadao Akizawa, Keiko Tanaka-Amino, Tetsuro Otsuka, Yusuke Yamaguchi. Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients.
American journal of nephrology.
2021; 52(9):702-713. doi:
10.1159/000519043. [PMID: 34628408] - Tadao Akizawa, Mai Ueno, Takanori Shiga, Michael Reusch. Oral roxadustat three times weekly in ESA-naïve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies.
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
2020 Dec; 24(6):628-641. doi:
10.1111/1744-9987.13468. [PMID: 31891449] - Robert Provenzano, James Tumlin, Raja Zabaneh, James Chou, Stefan Hemmerich, Thomas B Neff, K-H Peony Yu. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.
Journal of clinical pharmacology.
2020 11; 60(11):1432-1440. doi:
10.1002/jcph.1648. [PMID: 32603526] - Victoria H Ko, Lumeng J Yu, Duy T Dao, Xiaoran Li, Jordan D Secor, Lorenzo Anez-Bustillos, Bennet S Cho, Amy Pan, Paul D Mitchell, Hiroko Kishikawa, Mark Puder. Roxadustat (FG-4592) accelerates pulmonary growth, development, and function in a compensatory lung growth model.
Angiogenesis.
2020 11; 23(4):637-649. doi:
10.1007/s10456-020-09735-9. [PMID: 32666268] - Christian Görgens, Sven Guddat, Christina Bosse, Andre Knoop, Hans Geyer, Mario Thevis. Implementation of the HIF activator IOX-2 in routine doping controls - Pilot study data.
Drug testing and analysis.
2020 Nov; 12(11-12):1614-1619. doi:
10.1002/dta.2914. [PMID: 32809277] - Haidi Huang, Xin Wang, Xue Zhang, Hongbo Wang, Wanglin Jiang. Roxadustat attenuates experimental pulmonary fibrosis in vitro and in vivo.
Toxicology letters.
2020 Oct; 331(?):112-121. doi:
10.1016/j.toxlet.2020.06.009. [PMID: 32534005] - Fu Han, Gaofeng Wu, Shichao Han, Zhenzhen Li, Yanhui Jia, Lu Bai, Xiaoqiang Li, Kejia Wang, Fangfang Yang, Jian Zhang, Xujie Wang, Hao Guan, Su Linlin, Juntao Han, Dahai Hu. Hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat (FG-4592) alleviates sepsis-induced acute lung injury.
Respiratory physiology & neurobiology.
2020 10; 281(?):103506. doi:
10.1016/j.resp.2020.103506. [PMID: 32726645] - Julia Günter, Roland H Wenger, Carsten C Scholz. Inhibition of firefly luciferase activity by a HIF prolyl hydroxylase inhibitor.
Journal of photochemistry and photobiology. B, Biology.
2020 Sep; 210(?):111980. doi:
10.1016/j.jphotobiol.2020.111980. [PMID: 32745950] - Ughetta Del Balzo, Pierre E Signore, Gail Walkinshaw, Todd W Seeley, Mitchell C Brenner, Qingjian Wang, Guangjie Guo, Michael P Arend, Lee A Flippin, F Aisha Chow, David C Gervasi, Christian H Kjaergaard, Ingrid Langsetmo, Volkmar Guenzler, David Y Liu, Steve J Klaus, Al Lin, Thomas B Neff. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
The Journal of pharmacology and experimental therapeutics.
2020 08; 374(2):342-353. doi:
10.1124/jpet.120.265181. [PMID: 32487538] - Zhanhong Hu, Hong Tao, Aiming Shi, Jie Pan. The efficacy and economic evaluation of roxadustat treatment for anemia in patients with kidney disease not receiving dialysis.
Expert review of pharmacoeconomics & outcomes research.
2020 Aug; 20(4):411-418. doi:
10.1080/14737167.2020.1747436. [PMID: 32249625] - Markus S Anker, Javed Butler, Stefan D Anker. Roxadustat for Anemia in Patients with Chronic Kidney Disease.
The New England journal of medicine.
2020 07; 383(1):e3. doi:
NULL. [PMID: 32609998] - Katarzyna Zielniok, Anna Burdzinska, Leszek Paczek. Roxadustat for Anemia in Patients with Chronic Kidney Disease.
The New England journal of medicine.
2020 07; 383(1):e3. doi:
NULL. [PMID: 32609999] - Rajesh Mohandas, Mark S Segal. Roxadustat for Anemia in Patients with Chronic Kidney Disease.
The New England journal of medicine.
2020 07; 383(1):e3. doi:
NULL. [PMID: 32610000] - Hitesh H Shah, Steven Fishbane. Roxadustat for Anemia in Patients with Chronic Kidney Disease.
The New England journal of medicine.
2020 07; 383(1):e3. doi:
NULL. [PMID: 32610001] - Jingyuan Xie, Nan Chen. Roxadustat for Anemia in Patients with Chronic Kidney Disease. Reply.
The New England journal of medicine.
2020 07; 383(1):e3. doi:
NULL. [PMID: 32610002] - Joshua M Kaplan. Roxadustat for Anemia in Patients with Chronic Kidney Disease. Reply.
The New England journal of medicine.
2020 07; 383(1):e3. doi:
NULL. [PMID: 32610003] - Tadao Akizawa, Manabu Iwasaki, Yusuke Yamaguchi, Yoshikatsu Majikawa, Michael Reusch. Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.
Journal of the American Society of Nephrology : JASN.
2020 07; 31(7):1628-1639. doi:
10.1681/asn.2019060623. [PMID: 32493693] - Hiroko Deguchi, Masataka Ikeda, Tomomi Ide, Tomonori Tadokoro, Soichiro Ikeda, Kosuke Okabe, Akihito Ishikita, Keita Saku, Shouji Matsushima, Hiroyuki Tsutsui. Roxadustat Markedly Reduces Myocardial Ischemia Reperfusion Injury in Mice.
Circulation journal : official journal of the Japanese Circulation Society.
2020 05; 84(6):1028-1033. doi:
10.1253/circj.cj-19-1039. [PMID: 32213720] - Junduo Liu, Afang Zhang, John C Hayden, Akshaya Srikanth Bhagavathula, Fatema Alshehhi, Giulia Rinaldi, Vasileios Kontogiannis, Jamal Rahmani. Roxadustat (FG-4592) treatment for anemia in dialysis-dependent (DD) and not dialysis-dependent (NDD) chronic kidney disease patients: A systematic review and meta-analysis.
Pharmacological research.
2020 05; 155(?):104747. doi:
10.1016/j.phrs.2020.104747. [PMID: 32171893] - Tadao Akizawa, Tetsuro Otsuka, Michael Reusch, Mai Ueno. Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study.
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
2020 Apr; 24(2):115-125. doi:
10.1111/1744-9987.12888. [PMID: 31222951] - Christina M Wyatt, Tilman B Drueke. Inhibition of HIF prolyl-hydroxylase domain to correct anemia in patients with chronic kidney disease.
Kidney international.
2020 04; 97(4):639-642. doi:
10.1016/j.kint.2019.12.005. [PMID: 32200855] - Yang Liu, Jingyi Wang, Di Chen, Wendy R Kam, David A Sullivan. The Role of Hypoxia-Inducible Factor 1α in the Regulation of Human Meibomian Gland Epithelial Cells.
Investigative ophthalmology & visual science.
2020 03; 61(3):1. doi:
10.1167/iovs.61.3.1. [PMID: 32150252] - Kazuya Kabei, Yu Tateishi, Masayuki Shiota, Mayuko Osada-Oka, Shunji Nishide, Junji Uchida, Tatsuya Nakatani, Shinji Matsunaga, Takehiro Yamaguchi, Shuhei Tomita, Katsuyuki Miura. Effects of orally active hypoxia inducible factor alpha prolyl hydroxylase inhibitor, FG4592 on renal fibrogenic potential in mouse unilateral ureteral obstruction model.
Journal of pharmacological sciences.
2020 Mar; 142(3):93-100. doi:
10.1016/j.jphs.2019.12.002. [PMID: 31866051] - Richard A Voit, Vijay G Sankaran. Stabilizing HIF to Ameliorate Anemia.
Cell.
2020 01; 180(1):6. doi:
10.1016/j.cell.2019.12.010. [PMID: 31951520] - Tadao Akizawa, Yusuke Yamaguchi, Tetsuro Otsuka, Michael Reusch. A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
Nephron.
2020; 144(8):372-382. doi:
10.1159/000508100. [PMID: 32580188] - Xue Li, Yu Zou, Jia Xing, Yuan-Yuan Fu, Kai-Yue Wang, Peng-Zhi Wan, Xiao-Yue Zhai. Pretreatment with Roxadustat (FG-4592) Attenuates Folic Acid-Induced Kidney Injury through Antiferroptosis via Akt/GSK-3β/Nrf2 Pathway.
Oxidative medicine and cellular longevity.
2020; 2020(?):6286984. doi:
10.1155/2020/6286984. [PMID: 32051732] - Xingzhong Zhang, Yangming Zhang, Pengcheng Wang, Song-Yang Zhang, Yongqiang Dong, Guangyi Zeng, Yu Yan, Lulu Sun, Qing Wu, Huiying Liu, Bo Liu, Wei Kong, Xian Wang, Changtao Jiang. Adipocyte Hypoxia-Inducible Factor 2α Suppresses Atherosclerosis by Promoting Adipose Ceramide Catabolism.
Cell metabolism.
2019 11; 30(5):937-951.e5. doi:
10.1016/j.cmet.2019.09.016. [PMID: 31668872] - Rui-Yan Xie, Xue-Ling Fang, Xiao-Bin Zheng, Wei-Ze Lv, Yi-Jie Li, Hamze Ibrahim Rage, Qiao-Lan He, Wei-Ping Zhu, Tong-Xia Cui. Salidroside and FG-4592 ameliorate high glucose-induced glomerular endothelial cells injury via HIF upregulation.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2019 Oct; 118(?):109175. doi:
10.1016/j.biopha.2019.109175. [PMID: 31351423] - Nan Chen, Chuanming Hao, Bi-Cheng Liu, Hongli Lin, Caili Wang, Changying Xing, Xinling Liang, Gengru Jiang, Zhengrong Liu, Xuemei Li, Li Zuo, Laimin Luo, Jianqin Wang, Ming-Hui Zhao, Zhihong Liu, Guang-Yan Cai, Li Hao, Robert Leong, Chunrong Wang, Cameron Liu, Thomas Neff, Lynda Szczech, Kin-Hung P Yu. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.
The New England journal of medicine.
2019 09; 381(11):1011-1022. doi:
10.1056/nejmoa1901713. [PMID: 31340116] - Nan Chen, Chuanming Hao, Xiaomei Peng, Hongli Lin, Aiping Yin, Li Hao, Ye Tao, Xinling Liang, Zhengrong Liu, Changying Xing, Jianghua Chen, Laimin Luo, Li Zuo, Yunhua Liao, Bi-Cheng Liu, Robert Leong, Chunrong Wang, Cameron Liu, Thomas Neff, Lynda Szczech, Kin-Hung P Yu. Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis.
The New England journal of medicine.
2019 09; 381(11):1001-1010. doi:
10.1056/nejmoa1813599. [PMID: 31340089] - Joshua Kaplan. Roxadustat and Anemia of Chronic Kidney Disease.
The New England journal of medicine.
2019 09; 381(11):1070-1072. doi:
10.1056/nejme1908978. [PMID: 31340090] - Gunnar Schley, Bernd Klanke, Joanna Kalucka, Valentin Schatz, Christoph Daniel, Marleen Mayer, Margarete Goppelt-Struebe, Martin Herrmann, Margret Thorsteinsdottir, Runolfur Palsson, Angelika Beneke, Dörthe M Katschinski, Nicolai Burzlaff, Kai-Uwe Eckardt, Alexander Weidemann, Jonathan Jantsch, Carsten Willam. Mononuclear phagocytes orchestrate prolyl hydroxylase inhibition-mediated renoprotection in chronic tubulointerstitial nephritis.
Kidney international.
2019 08; 96(2):378-396. doi:
10.1016/j.kint.2019.02.016. [PMID: 31146971] - Charandeep Singh, George Hoppe, Vincent Tran, Leah McCollum, Youstina Bolok, Weilin Song, Amit Sharma, Henri Brunengraber, Jonathan E Sears. Serine and 1-carbon metabolism are required for HIF-mediated protection against retinopathy of prematurity.
JCI insight.
2019 07; 4(14):. doi:
10.1172/jci.insight.129398. [PMID: 31341109] - Neil S Sanghani, Volker H Haase. Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience.
Advances in chronic kidney disease.
2019 07; 26(4):253-266. doi:
10.1053/j.ackd.2019.04.004. [PMID: 31477256] - Tadao Akizawa, Manabu Iwasaki, Tetsuro Otsuka, Michael Reusch, Toshihiro Misumi. Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial.
Advances in therapy.
2019 06; 36(6):1438-1454. doi:
10.1007/s12325-019-00943-4. [PMID: 30953333] - Tomohisa Shibata, Yuki Nomura, Akitsugu Takada, Mai Ueno, Masataka Katashima, Rie Yazawa, Kenichi Furihata. Evaluation of Food and Spherical Carbon Adsorbent Effects on the Pharmacokinetics of Roxadustat in Healthy Nonelderly Adult Male Japanese Subjects.
Clinical pharmacology in drug development.
2019 04; 8(3):304-313. doi:
10.1002/cpdd.597. [PMID: 29966038] - Sohita Dhillon. Roxadustat: First Global Approval.
Drugs.
2019 Apr; 79(5):563-572. doi:
10.1007/s40265-019-01077-1. [PMID: 30805897] - Dorien Groenendaal-van de Meent, Martin den Adel, Jan van Dijk, Begona Barroso-Fernandez, Rachid El Galta, Georg Golor, Marloes Schaddelee. Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Safety, and Tolerability of Roxadustat in Healthy Subjects.
European journal of drug metabolism and pharmacokinetics.
2018 Dec; 43(6):685-692. doi:
10.1007/s13318-018-0480-z. [PMID: 29752643] - T Shibata, Y Nomura, A Takada, S Aoki, M Katashima, H Murakami. Evaluation of the effect of lanthanum carbonate hydrate on the pharmacokinetics of roxadustat in non-elderly healthy adult male subjects.
Journal of clinical pharmacy and therapeutics.
2018 Oct; 43(5):633-639. doi:
10.1111/jcpt.12729. [PMID: 29981285] - Amit A Joharapurkar, Vrajesh B Pandya, Vishal J Patel, Ranjit C Desai, Mukul R Jain. Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases.
Journal of medicinal chemistry.
2018 08; 61(16):6964-6982. doi:
10.1021/acs.jmedchem.7b01686. [PMID: 29712435] - Yunwen Yang, Xiaowen Yu, Yue Zhang, Guixia Ding, Chunhua Zhu, Songming Huang, Zhanjun Jia, Aihua Zhang. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury.
Clinical science (London, England : 1979).
2018 04; 132(7):825-838. doi:
10.1042/cs20171625. [PMID: 29581249] - Lucia Del Vecchio, Francesco Locatelli. Roxadustat in the treatment of anaemia in chronic kidney disease.
Expert opinion on investigational drugs.
2018 Jan; 27(1):125-133. doi:
10.1080/13543784.2018.1417386. [PMID: 29254377]